World
Archived — This article has been archived. The information may be outdated.
Girl's death in China exposes gene-editing trial gaps
The Hindu··27 Jul
A six-year-old girl with Snijders Blok-Campeau syndrome died in China in March 2025 after receiving an experimental base-editing therapy targeting her brain, according to an investigation by Science and Retraction Watch. Her family had contributed about $860,000 toward the research. She developed fever and kidney damage within days and died a week after the injection.
Prism
What It Means For You
- The case highlights risks families face when seeking experimental treatments for rare disorders abroad.
- It shows how investigator-initiated trials can proceed without national regulator review in some countries.
- The episode renews scrutiny of journal publication standards for undisclosed trial outcomes.
What's Happening
- A six-year-old girl in China died in March 2025 after an experimental brain gene-editing therapy.
- The family had paid roughly $860,000 to fund research for her rare CHD3 gene disorder.
- She developed fever and kidney damage within days and died a week after the injection.
First-in-Human Trials Under the Microscope
- The trial proceeded without review from China's national drug regulator, an investigation found.
- Monkey studies had shown liver injury in all treated animals before the human trial began.
- Neither researchers nor the hospital disclosed the girl's death publicly at the time.
all-newseditors-picks
